Author information
1
Centers for Disease Control and Prevention, Atlanta, GA, USA.
2
Maryland Department of Health and Mental Hygiene, Baltimore, MD, USA.
3
The Johns Hopkins University, Baltimore, MD, USA.
4
University of Illinois at Chicago, Chicago, IL, USA.
5
University of Chicago, Chicago, IL, USA.
6
Communicable Disease Epidemiology and Immunization Section at Public Health-Seattle and King County, Seattle, WA, USA.
7
University of Washington, Seattle, WA, USA.
Abstract
Restrictive policies on access to new, curative hepatitis C treatments represent a substantial barrier to treating patients infected with hepatitis C. This case series demonstrates challenges experienced by patients and practitioners in accessing these treatments and highlights several strategies for navigating the treatment preauthorization process.